GlassScriptPhysician profile
Karla B Saint Andre
NPI 1609261411
$5,262.40
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2020: $336 · 2021: $1,320 · 2022: $2,123 · 2023: $1,058 · 2024: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,213 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,212.52 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,164.78 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $557.41 | 2020-2023 | Mounjaro, Jardiance, Taltz |
| Amgen INC. | $537.43 | 2021-2022 | |
| Dexcom, INC. | $427.65 | 2021-2022 | |
| Radius Health, INC. | $382.18 | 2020-2024 | Tymlos |
| Alexion Pharmaceuticals, INC. | $345.56 | 2019-2024 | Strensiq |
| Corcept Therapeutics | $281.11 | 2021-2023 | Korlym |
| Abbott Laboratories | $239.84 | 2022-2023 | Thoratec Heartmate 3 Lvas Implant Kit, Freestyle Libre 3 |
| Medtronic, INC. | $159.21 | 2021-2022 | |
| Vivus LLC | $136.95 | 2021-2022 | |
| Nevro Corp. | $132.08 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $125.00 | 2023 | Imcivree |
| Sanofi-Aventis U.S. LLC | $121.79 | 2021-2023 | |
| Horizon Therapeutics Plc | $115.51 | 2023 | Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.61 | 2022-2023 | Jardiance |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.61 | 2021-2023 | Cycloset |
| Currax Pharmaceuticals LLC | $56.52 | 2023 | Contrave, Nexletol |
| Astrazeneca Pharmaceuticals LP | $54.93 | 2020-2021 | |
| Ironwood Pharmaceuticals, INC | $52.61 | 2022-2024 | |
| Janssen Biotech, INC. | $50.55 | 2021-2022 | |
| Intuity Medical INC | $24.68 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Ultragenyx Pharmaceutical INC. | $22.25 | 2022 | |
| Insulet Corporation | $21.45 | 2021 | |
| Xeris Pharmaceuticals, INC. | $20.34 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $19.16 | 2022 | |
| Tandem Diabetes Care, INC. | $18.34 | 2022 | |
| Ucb, INC. | $13.62 | 2022 | |
| Ibsa Pharma INC. | $13.23 | 2023 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karla Saint Andre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.